Organization
Context Therapeutics
1 clinical trial
1 abstract
Clinical trial
An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer (ELONA)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Abstract
OATH trial: A phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer—Preliminary results.Org: Thomas Jefferson University Hospital, Abington Hospital-Jefferson Health, Gyn Onc Inst, Sidney Kimmel Medical College at Thomas Jefferson University, Thomas Jefferson University,